Benitec Biopharma (BNTC) Competitors

Benitec Biopharma (NASDAQ:BNTC) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.

Is BNTC or BHVN more profitable?

Benitec Biopharma's return on equity of -44.61% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-44.61%	-41.25%
Biohaven	N/A	-225.12%	-158.89%

Which has more volatility & risk, BNTC or BHVN?

Benitec Biopharma has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in BNTC or BHVN?

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 16.0% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has better valuation & earnings, BNTC or BHVN?

Benitec Biopharma has higher revenue and earnings than Biohaven. Benitec Biopharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	5,433.75	-$21.75M	-$1.51	-10.97
Biohaven	N/A	N/A	-$408.17M	-$9.36	-1.67

Does the media favor BNTC or BHVN?

In the previous week, Biohaven had 9 more articles in the media than Benitec Biopharma. MarketBeat recorded 11 mentions for Biohaven and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.91 beat Biohaven's score of 0.16 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Positive
Biohaven	Neutral

Does the MarketBeat Community favor BNTC or BHVN?

Biohaven received 211 more outperform votes than Benitec Biopharma when rated by MarketBeat users. Likewise, 67.43% of users gave Biohaven an outperform vote while only 65.89% of users gave Benitec Biopharma an outperform vote.

Company	Underperform	Outperform
Benitec Biopharma	Outperform Votes 199 65.89%	Underperform Votes 103 34.11%
Biohaven	Outperform Votes 410 67.43%	Underperform Votes 198 32.57%

Do analysts prefer BNTC or BHVN?

Benitec Biopharma currently has a consensus price target of $24.71, suggesting a potential upside of 49.24%. Biohaven has a consensus price target of $59.46, suggesting a potential upside of 280.07%. Given Biohaven's higher probable upside, analysts clearly believe Biohaven is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22
Biohaven	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.07

Summary

Biohaven beats Benitec Biopharma on 9 of the 16 factors compared between the two stocks.